WO2008125279A3 - Administration ciblée de cellules stromales mésenchymateuses avec ablation auriculaire par cathéter de radiofréquence - Google Patents

Administration ciblée de cellules stromales mésenchymateuses avec ablation auriculaire par cathéter de radiofréquence Download PDF

Info

Publication number
WO2008125279A3
WO2008125279A3 PCT/EP2008/002854 EP2008002854W WO2008125279A3 WO 2008125279 A3 WO2008125279 A3 WO 2008125279A3 EP 2008002854 W EP2008002854 W EP 2008002854W WO 2008125279 A3 WO2008125279 A3 WO 2008125279A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
mscs
myocardium
lesions
present
Prior art date
Application number
PCT/EP2008/002854
Other languages
English (en)
Other versions
WO2008125279A2 (fr
WO2008125279A9 (fr
Inventor
Joerg Zehelein
Original Assignee
Universitaetsklinikum Heidelbe
Joerg Zehelein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Heidelbe, Joerg Zehelein filed Critical Universitaetsklinikum Heidelbe
Publication of WO2008125279A2 publication Critical patent/WO2008125279A2/fr
Publication of WO2008125279A9 publication Critical patent/WO2008125279A9/fr
Publication of WO2008125279A3 publication Critical patent/WO2008125279A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]

Abstract

La présente invention porte sur des cellules souches mésenchymateuses (MSC) pour le traitement des maladies cardiaques chez un mammifère, caractérisées par le fait que le traitement comprend une administration de MSC ou d'une préparation pharmaceutique comprenant des MSC et qu'avant l'administration, des lésions sont introduites dans le myocarde dudit mammifère, lesdites lésions n'affectant sensiblement pas la fonction dudit myocarde. La présente invention porte également sur des MSC pour la constitution d'un stimulateur cardiaque biologique dans un mammifère. De plus, la présente invention porte sur une méthode d'implantation contrôlée de cellules souches mésenchymateuses (MSC) dans le tissu myocardique d'un mammifère. Cette méthode comprend les étapes consistant à : a) prendre une préparation pharmaceutique comprenant des MSC devant être implantées au dit mammifère, b) introduire des lésions dans le myocarde dudit mammifère, lesdites lésions ne gênant sensiblement pas la fonction dudit myocarde, et c) administrer ladite préparation pharmaceutique comprenant des MSC au dit mammifère par perfusion. La présente invention concerne en outre une méthode pour constituer un stimulateur cardiaque biologique dans un mammifère, une méthode pour traiter un dysfonctionnement du centre rythmogène et/ou une maladie dégénérative du nœud sino-auriculaire et/ou atrio-ventriculaire dans le myocarde, et des complications et troubles apparentés chez un mammifère au moyen de ladite méthode d'implantation contrôlée de cellules souches mésenchymateuses (MSC) dans le tissu myocardique d'un mammifère.
PCT/EP2008/002854 2007-04-11 2008-04-10 Administration ciblée de cellules stromales mésenchymateuses avec ablation auriculaire par cathéter de radiofréquence WO2008125279A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92309207P 2007-04-11 2007-04-11
US60/923,092 2007-04-11

Publications (3)

Publication Number Publication Date
WO2008125279A2 WO2008125279A2 (fr) 2008-10-23
WO2008125279A9 WO2008125279A9 (fr) 2008-12-18
WO2008125279A3 true WO2008125279A3 (fr) 2009-07-23

Family

ID=39631460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/002854 WO2008125279A2 (fr) 2007-04-11 2008-04-10 Administration ciblée de cellules stromales mésenchymateuses avec ablation auriculaire par cathéter de radiofréquence

Country Status (1)

Country Link
WO (1) WO2008125279A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006701A1 (fr) * 1998-07-31 2000-02-10 Genzyme Corporation Amelioration du fonctionnement cardiaque par transplantation de cellules souches mesenchymateuses
WO2004037188A2 (fr) * 2002-10-22 2004-05-06 Osiris Therapeutics, Inc. Regeneration du muscle cardiaque a l'aide de cellules mesenchymateuses
US20060234375A1 (en) * 2004-09-30 2006-10-19 Doronin Sergey V Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006701A1 (fr) * 1998-07-31 2000-02-10 Genzyme Corporation Amelioration du fonctionnement cardiaque par transplantation de cellules souches mesenchymateuses
WO2004037188A2 (fr) * 2002-10-22 2004-05-06 Osiris Therapeutics, Inc. Regeneration du muscle cardiaque a l'aide de cellules mesenchymateuses
US20060234375A1 (en) * 2004-09-30 2006-10-19 Doronin Sergey V Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
COHEN ET AL: "A Caveat Emptor for myocardial regeneration: Mechanical without electrical recovery will not suffice", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, GB, vol. 42, no. 2, 24 January 2007 (2007-01-24), pages 285 - 288, XP005853925, ISSN: 0022-2828 *
JUMRUSSIRIKUL P ET AL: "PROSPECTIVE COMPARISON OF TEMPERATURE GUIDED MICROWAVE AND RADIOFREQUENCY CATHETER ABLATION IN THE SWINE HEART", PACE - PACING AND CLINICAL ELECTROPHYSIOLOGY, BLACWELL FUTURA PUBLISHING, MALDEN, MA, US, vol. 21, no. 7, 1 July 1998 (1998-07-01), pages 1364 - 1374, XP000772449, ISSN: 0147-8389 *
MOCINI DAVID ET AL: "STEM CELL THERAPY FOR CARDIAC ARRHYTHMIAS", ITALIAN HEART JOURNAL, CEPI, CENTRO EDITORIALE PUBBLICITARIO ITALIANO, ROME, IT, vol. 6, no. 3, 1 March 2005 (2005-03-01), pages 267 - 271, XP009079658, ISSN: 1129-471X *
POTAPOVA I ET AL: "Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 94, no. 7, 1 April 2004 (2004-04-01), pages 952 - 959, XP002988996, ISSN: 0009-7330 *
ROSEN M R ET AL: "Genes, stem cells and biological pacemakers", CARDIOVASCULAR RESEARCH, OXFORD UNIVERSITY PRESS, vol. 64, no. 1, 1 October 2004 (2004-10-01), pages 12 - 23, XP004567981, ISSN: 0008-6363 *
ROSEN M R: "Biological pacemaking: In our lifetime?", HEART RHYTHM, ELSEVIER, vol. 2, no. 4, 1 April 2005 (2005-04-01), pages 418 - 428, XP004819482, ISSN: 1547-5271 *
SCHWEIZER PATRICK A ET AL: "Atrial-radiofrequency catheter ablation mediated targeting of mesenchymal stromal cells", STEM CELLS (MIAMISBURG), vol. 25, no. 6, June 2007 (2007-06-01), pages 1546 - 1551, XP002527088, ISSN: 1066-5099 *
TWIDALE ET AL: "Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC., ST. LOUIS, MO, US, vol. 136, no. 4, 1 October 1998 (1998-10-01), pages 647 - 657, XP005690508, ISSN: 0002-8703 *

Also Published As

Publication number Publication date
WO2008125279A2 (fr) 2008-10-23
WO2008125279A9 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
Chong et al. Cardiac regeneration using pluripotent stem cells—progression to large animal models
Fischer et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase
Veselka et al. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years
WO2006121532A3 (fr) Traitement des cardiopathies
WO2011057249A3 (fr) Traitement d'une cardiopathie
WO2011057251A3 (fr) Traitement d'une cardiopathie
WO2005000245A3 (fr) Compositions et methodes destinees a augmenter l'activite de la telomerase
WO2007079268A3 (fr) Procedes et appareil d’ablation de tissu cardiaque
WO2006099015A3 (fr) Carotenoides, analogues de carotenoides ou derives de carotenoides permettant de traiter les troubles proliferatifs
CA2747794A1 (fr) Traitement des poumons et des maladies et troubles pulmonaires
Wu et al. Beneficial effects of the extract from Corydalis yanhusuo in rats with heart failure following myocardial infarction
WO2009073050A3 (fr) Utilisation de la curcumine pour bloquer la formation de tumeur cérébrale in vivo
WO2012106367A3 (fr) Cellules souches pluripotentes et procédé de stimulation et d'extraction de cellules souches pluripotentes non embryonnaires à partir de cellules provenant du sang d'un animal et utilisation des cellules souches pluripotentes reconstituées pour traiter les maladies telles que la pneumopathie obstructive chronique
Yamazaki et al. Left atrial coronary perfusion territories in isolated sheep hearts: implications for atrial fibrillation maintenance
Chachques et al. From dynamic to cellular cardiomyoplasty
WO2008079412B1 (fr) Procédés et compositions pour traiter les arythmies
WO2008125279A3 (fr) Administration ciblée de cellules stromales mésenchymateuses avec ablation auriculaire par cathéter de radiofréquence
WO2008011133A3 (fr) COMPOSITIONS de cellules souches mésenchymateuses (CSM) à passage tardif
CN102120035A (zh) 一种靶向至白色脂肪组织治疗代谢综合征的新型靶向药物
Qu et al. Induction of substantial myocardial regeneration by an active fraction of the Chinese herb Rosa laevigata Michx
Tariq et al. Use of stem cells in ischemic heart disease
KR102017386B1 (ko) 이식된 지방세포의 생착 증진용 조성물 및 지방 이식용 세포 치료제 조성물
Van der Wall A broken heart: repair needed?
WO2023044689A1 (fr) Timbre immunométabolique pour infarctus du myocarde, son procédé de préparation et son application
RU2006100561A (ru) Способ лечения онкологических забелеваний

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08735162

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08735162

Country of ref document: EP

Kind code of ref document: A2